Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

161
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
161
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

182
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
182
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

121
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
121

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Interlaboratory performance testing on EPIC v2.0 CNS tumor profiling demonstrates high reproducibility of tumor classification but reveals the need for harmonized copy number variation reporting.

Brain pathology (Zurich, Switzerland)·2026
Same author

Needle-track metastasis in diffuse intrinsic pontine glioma: Need for a standardized surgical strategy?

Neuro-oncology advances·2026
Same author

Incomplete tumor resection, central neuroradiological review, and second surgery in pediatric patients with intracranial ependymoma treated in the E-HIT2000 trial.

Journal of neurosurgery. Pediatrics·2026
Same author

APTw CEST MRI in therapy-naive IDH-wildtype glioblastoma: insights into tumor heterogeneity and molecular subtypes.

Journal of neuro-oncology·2026
Same author

L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial.

Nature communications·2026
Same author

Microglia-glioblastoma crosstalk mediates glioblastoma invasion at the far infiltration zone.

Immunity·2026

Related Experiment Video

Updated: Dec 18, 2025

Author Spotlight: A Single-Entry Point Endoscopic Intraventricular Approach for Third Ventriculostomy and Pineal Biopsy
03:13

Author Spotlight: A Single-Entry Point Endoscopic Intraventricular Approach for Third Ventriculostomy and Pineal Biopsy

Published on: June 28, 2024

687

[Pediatric brain tumors].

Torsten Pietsch1

  • 1Institut für Neuropathologie, Hirntumor-Referenzzentrum der DGNN, Universitätsklinikum Bonn, Venusberg-Campus 1, 53127, Bonn, Deutschland. t.pietsch@uni-bonn.de.

Pathologie (Heidelberg, Germany)
|September 27, 2023
PubMed
Summary

Pediatric central nervous system (CNS) tumors require precise neuropathological classification for effective treatment. Recent advancements, including genetic and epigenetic analysis, enhance diagnostic accuracy and guide novel therapeutic strategies for childhood brain tumors.

Keywords:
CNS tumorsEmbryonal tumorsGliomasNeuropathologyWHO classification

More Related Videos

Co-culture of Glutamatergic Neurons and Pediatric High-Grade Glioma Cells Into Microfluidic Devices to Assess Electrical Interactions
07:39

Co-culture of Glutamatergic Neurons and Pediatric High-Grade Glioma Cells Into Microfluidic Devices to Assess Electrical Interactions

Published on: November 17, 2021

3.5K
Creating Anatomically Accurate and Reproducible Intracranial Xenografts of Human Brain Tumors
11:14

Creating Anatomically Accurate and Reproducible Intracranial Xenografts of Human Brain Tumors

Published on: September 24, 2014

15.8K

Related Experiment Videos

Last Updated: Dec 18, 2025

Author Spotlight: A Single-Entry Point Endoscopic Intraventricular Approach for Third Ventriculostomy and Pineal Biopsy
03:13

Author Spotlight: A Single-Entry Point Endoscopic Intraventricular Approach for Third Ventriculostomy and Pineal Biopsy

Published on: June 28, 2024

687
Co-culture of Glutamatergic Neurons and Pediatric High-Grade Glioma Cells Into Microfluidic Devices to Assess Electrical Interactions
07:39

Co-culture of Glutamatergic Neurons and Pediatric High-Grade Glioma Cells Into Microfluidic Devices to Assess Electrical Interactions

Published on: November 17, 2021

3.5K
Creating Anatomically Accurate and Reproducible Intracranial Xenografts of Human Brain Tumors
11:14

Creating Anatomically Accurate and Reproducible Intracranial Xenografts of Human Brain Tumors

Published on: September 24, 2014

15.8K

Area of Science:

  • Neuropathology
  • Pediatric Oncology
  • Molecular Biology

Context:

  • Pediatric central nervous system (CNS) tumors exhibit distinct characteristics compared to adult tumors.
  • Accurate classification is crucial for treatment decisions and clinical trials.
  • The World Health Organization (WHO) classification (2021) provides a standardized diagnostic framework.

Purpose:

  • To highlight the importance of accurate neuropathological classification of pediatric CNS tumors.
  • To emphasize the role of advanced diagnostic methods in improving precision.
  • To underscore the impact of classification on therapeutic strategies and research.

Summary:

  • Pediatric CNS tumors necessitate precise classification using standardized histological, immunohistological, and molecular pathological methods.
  • The current WHO classification (2021) ensures uniform diagnosis globally, facilitating data comparability.
  • Identification of genetic alterations and epigenetic signatures has significantly refined the classification of pediatric brain tumors.

Impact:

  • Improved classification precision aids in targeted therapy development for pediatric brain tumors.
  • Understanding key molecules and signaling pathways opens avenues for mechanism-based treatments.
  • Standardized classification supports international collaboration in research and clinical data analysis.